We first examined the frequency and type of TP53 mutations in patients with advanced NSCLC positive for activating mutations (L858R or exon-19 deletions) of EGFR with the use of data from the MSK-MET study24 that were accessed via the cBioPortal database25,26. This evidence concerns the gene TP53 and non-small cell lung carcinoma.